Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer-Reference-Cited by-同舟云学术

Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer

Published:2020-03-06 Issue:6 Volume:59 Page:713-722
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Claessens Anouk K. M.¹²^ORCID,Erdkamp Frans L. G.¹,Lopez-Yurda Marta³,Bouma Jeanette M.⁴,Rademaker-Lakhai Jeany M.⁵,Honkoop Aafke H.⁶,de Graaf Hiltje⁷,Tjan-Heijnen Vivianne C. G.²,Bos Monique E. M. M.⁸,

Affiliation:

1. Department of Medical Oncology, Zuyderland Medical Centre, Geleen, The Netherlands;

2. Department of Medical Oncology, GROW – School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands;

3. Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands;

4. Department of Trial Registration, Comprehensive Cancer Centre the Netherlands, Rotterdam, The Netherlands;

5. Dutch Breast Cancer Research Group, BOOG study Centre, Amsterdam, The Netherlands;

6. Department of Medical Oncology, Isala Clinic, Zwolle, The Netherlands;

7. Department of Medical Oncology, Leeuwarden Medical Centre, Leeuwarden, The Netherlands;

8. Department of Medical Oncology, Erasmus Medical Centre, Rotterdam, The Netherlands

Publisher

Informa UK Limited

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2020.1731923

Reference55 articles.

1. Noone A, Howlader N, Krapcho M, et al. SEER Cancer Statistics Review 1975–2015. Based on November 2017 SEER data submission, posted to SEER webiste April 18. Bethesda, MD: National Cancer Institute; 2018.

2. Improved survival in metastatic breast cancer 1985–2016

3. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

4. Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

5. Lack of Benefit of Maintenance Paclitaxel in First-Line Chemotherapy in Metastatic Breast Cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Burden of chemotherapy-induced myelosuppression among patients with ES-SCLC in US community oncology settings;Future Oncology;2022-11

2. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States;Journal of Managed Care & Specialty Pharmacy;2022-04

3. Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer;Acta Oncologica;2022-02-09

4. Aspectos clínicos y terapéuticos del carcinoma de mama metastásico triple negativo;Anales Médicos de la Asociación Médica del Centro Médico ABC;2022

5. Mathematical model of brain tumour growth with drug resistance;Communications in Nonlinear Science and Numerical Simulation;2021-12